Papers

Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil. (2025) Banke TG,  Regan MC,  Perszyk RE,  Zhang L, Xing H, Chen J, Won S, Simorowski N, Diaz ES, Kim S, Song R, Rong J, Zhou X, Chaudhary AF, Zhang J, Traynelis JF, McDaniels ED, Nitsche K, Roache S, Raymond CS, Low C-M, Myers SJ, Roche KW, Liang SH, Traynelis SF, Furukawa H, Yuan H (2025) Brain  Revised manuscript submitted.

Lemke JR, Eoli A, Krey I, Popp B, Strehlow V, Wittekind D, Vuorinen A-L, Aldhalaan HM, Baer S, de Saint Martin A, Hammer TB, Herman I, Hornemann F, Ingebrigtsen T, Lederer D, Lesca G, Marafie D,  Mathot M, Rosenfeld JA, Møller RS, Schelhaas HJ, Stillman C, Orsini A, Patel AD, Piard J, Veggiotti P, Vlaskamp DRM,Weckhuysen S, Traynelis SF, Benke TA, Heyne HO, Syrbe S, (2025) GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy. Molecular Psychiatry, Manuscript in press.

Yabumoto T, Kochoian BA, Coletta S, Laur O, Huang X, Bure CA, Ware C, Jin P, Traynelis SF, Papa SM. (2025) Striatal GluN2A gene suppression reduces L-DOPA-induced abnormal involuntary movements in parkinsonian rats. Neuropharmacology 279:110616.  PMID: 40744408

Chou C, Paredes CC, Summers B, Palmer-Johnson J, Trivedi A, Bhagwani A, Hansen KB, Kristensen AS, Gyoneva S, Swanger SA, Traynelis SF, Reed HO. (2025) The thrombin receptor PAR1 orchestrates changes in lymphatic endothelial cell junction morphology to augment lymphatic drainage during lung injury. Nature Cardiovasc Res 4(8):964-975. PMID: 40676263

Camp CR, Banke TG, Xing H, Yu K, Perszyk RE, Epplin MP, Akins NS, Zhang J, Benke TA, Yuan H, Liotta DC, Traynelis SF. (2025) Selective enhancement of the interneuron network and gamma-band power via GluN2C/GluN2D NMDA receptor potentiation. J Physiol 603(14):4027-4049. PMID: 40560934

Fritzemeier RG, Akins NS, Arcoria PJ, Paladugu S, Ullman EZ, Allen J, Sheikh R, Nocilla KA, McDaniels ED, Coleman EM, Antonoudiou P, D'Erasmo MP, Bartsch P, Sharma SK, Maguire J, Traynelis SF, Liotta DC. (2025) Thienopyrimidinone Derivatives as a GluN2B/C/D Biased, Positive Allosteric Modulator of the N-Methyl-d-Aspartate Receptor. J Med Chem 68(9):9303-9322. PMID: 40254917

Teoh J, Simko J, Camp CR, Liu CJ, Wang W, Williams D, Ma L, Soundararajan D, Martin C, Taylor NK, François E, Petri S, Kanber A, Ravichandra A, Pero ME, Bartolini F, Swayne TC, Lutz CM, Zuberi A, Rubinstein M, Hausman Kedem M, Yuan H, Gelinas JN, Sands TT, Harper SQ, Traynelis SF, Makinson CD, Frankel WN. (2025) Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy. Brain  doi: 10.1093/brain/awaf125. Online ahead of print. PMID: 40200555

Kang H, Epstein M, Banke TG, Perszyk R, Simorowski N, Paladugu S, Liotta DC, Traynelis SF, Furukawa H. (2025) Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor.Neuron 113(7):991-1005.e5. PMID: 39954679

Wang H, Dingledine RJ, Myers SJ, Traynelis SF, Fang C, Tan Y, Koszalka GW, Laskowitz DT. (2025) Clinical development of the GluN2B-selective NMDA receptor inhibitor NP10679 for the treatment of neurologic deficit after subarachnoid hemorrhage. J Pharmacol Exp Ther 392(1):100046. PMID: 39892986

Montanucci L, Brünger T, Bhattarai N, Boßelmann CM, Kim S, Allen JP, Zhang J, Klöckner C, Krey I, Fariselli P, May P, Lemke JR, Myers SJ, Yuan H, Traynelis SF, Lal D. (2025) Ligand distances as key predictors of pathogenicity and function in NMDA receptors. Hum Mol Genet 34(2):128-139. PMID: 39535073

Ullman EZ, Perszyk R E, Paladugu S, Fritzemeier R G, Akins N S, Jacobs L, Liotta D C, Traynelis S F. Mechanisms of action underlying conductance-modifying positive allosteric modulators of the NMDA receptor. Mol Pharmacol. 106(6): 334-353

Roh W S, Hong Yoo J, Dravid S M, Mannaioni G, Krizman E N, Wahl P, Robinson M B, Traynelis S F, Lee C J, Han K S. (2024) Astrocytic PAR1 and mGluR2/3 control synaptic glutamate time course at hippocampal CA1 synapses. Glia. 72(9): 1707-1724

Sullivan M T, Tidball P, Yan Y, Intson K, Chen W, Xu Y, Venkatesan S, Horsfall W, Georgiou J, Finnie P S B, Lambe E K, Traynelis S F, Salahpour A, Yuan H, Collingridge G L, Ramsey A J. (2024) Grin1 Y 647 S/+ Mice: A Preclinical Model of GRIN1 -Related Neurodevelopmental Disorder. bioRxiv. Preprint

Chou T H, Epstein M, Fritzemeier R G, Akins N S, Paladugu S, Ullman E Z, Liotta D C, Traynelis S F, Furukawa H. (2024) Molecular mechanism of ligand gating and opening of NMDA receptor. Nature. 632(8023): 209-217

Yi  F, Traynelis S F, Hansen K B. (2024) Selective Cell-Surface Expression of Triheteromeric NMDA Receptors. Methods Mol Biol. 2799: 55-77

Xu Y, Song R, Perszyk R E, Chen W, Kim S, Park K L, Allen J P, Nocilla K A, Zhang J, XiangWei W, Tankovic A, McDaniels E D, Sheikh R, Mizu R K, Karamchandani M M, Hu C, Kusumoto H, Pecha J, Cappuccio G, Gaitanis J, Sullivan J, Shashi V, Petrovski S, Jauss R T, Lee H K, Bozarth X, Lynch D R, Helbig I, Pierson T M, Boerkoel C F, Myers S J, Lemke J R, Benke T A, Yuan H, Traynelis S F. (2024) De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor. Cell Mol Life Sci. 81(1): 153

Banke T G, Traynelis S F, Barria A. (2024) Early expression of GluN2A-containing NMDA receptors in a model of fragile X syndrome. J Neurophysiol. 131(4): 768-777

Allen J P, Garber K B, Perszyk R E, Khayat C T, Kell S A, Kaneko M, Quindipan C, Saitta S, Ladda R L, Hewson S, Inbar-Feigenberg M, Prasad C, Prasad A N, Olewiler L, Mu W, Rosenthal L S, Scala M, Striano P, Zara F, McCullock T W, Jauss R T, Lemke J R, MacLean D M, Zhu C, Yuan H, Myers S J, Traynelis S F. (2024) Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants. Hum Mol Genet. 33(4): 355-373

Vieira M M, Peng S, Won S, Hong E, Inati S K, Thurm A, Thiam A H, Kim S, Myers S J, Badger J D, Traynelis S F, Lu W, Roche K W. (2024) A Frameshift Variant of GluN2A Identified in an Epilepsy Patient Results in NMDA Receptor Mistargeting. J Neurosci. 44(4): e0557232023 

Song R, Zhang J, Perszyk R E, Camp C R, Tang W, Kannan V, Li J, Xu Y, Chen J, Li Y, Liang S H, Traynelis S F, Yuan H. (2023) Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors. J Neurochem. 15942

Hanson J E, Yuan H, Perszyk R E, Banke T G, Xing H, Tsai M C, Menniti F S, Traynelis S F. (2024) Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacology. 49(1): 51-66

Romero C A, Lim J, Wang H, Wynne B M, Ma P, Jing Y, Liotta D C, D’Erasmo M, Traynelis S F, Eaton D C, Wall S M. (2023) Epithelial N-methyl-D-aspartate (NMDA) receptors mediate renal vasodilation by affecting kidney autoregulation. bioRxiv. Preprint

XiangWei W, Perszyk R E, Liu N, Xu Y, Bhattacharya S, Shaulsky G H, Smith-Hicks C, Fatemi A, Fry A E, Chandler K, Wang T, Vogt J, Cohen J S, Paciorkowski A R, Poduri A, Zhang Y, Wang S, Wang Y, Zhai Q, Fang F, Leng J, Garber K, Myers S J, Jauss R T, Park K L, Benke T A, Lemke J R, Yuan H, Jiang Y, Traynelis S F. (2023) Clinical and functional consequences of GRIA variants in patients with neurological diseases. Cell Mol Life Sci. 80(11): 345

Liu N, Li J, Gao K, Perszyk R E, Zhang J, Wang J, Wu Y, Jenkins A, Yuan H, Traynelis S F, Jiang Y. (2023) De novo CLPTM1 variants with reduced GABAA R current response in patients with epilepsy. Epilepsia. 64(11): 2968-2981

D’Erasmo M P, Akins N S, Ma P, Jing Y, Swanger S A, Sharma S K, Bartsch P W, Menaldino D S, Arcoria P J, Bui T T, Pons-Bennaceur A, Le P, Allen J P, Ullman E Z, Nocilla K A, Zhang J, Perszyk R E, Kim S, Acker T M, Taz A, Burton S L, Coe K, Fritzemeier R G, Burnashev N, Yuan H, Liotta D C, Traynelis S F. (2023) Development of a Dihydroquinoline-Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N-Methyl-d-aspartate Receptor. ACS Chem Neurosci. 14(17): 3059-3076 

Myers S J, Yuan H, Perszyk R E, Zhang J, Kim S, Nocilla K A, Allen J P, Bain J M, Lemke J R, Lal D, Benke T A, Traynelis S F. (2023) Classification of missense variants in the N-methyl-d-aspartate receptor GRIN gene family as gain- or loss-of-function. Hum Mol Genet. 32(19): 2857-2871

Camp C R, Vlachos A, Klöckner C, Krey I, Banke T G, Shariatzadeh N, Ruggiero S M, Galer P, Park K L, Caccavano A, Kimmel S, Yuan X, Yuan H, Helbig I, Benke T A, Lemke J R, Pelkey K A, McBain C J, Traynelis S F. (2023) Loss of Grin2a causes a transient delay in the electrophysiological maturation of hippocampal parvalbumin interneurons. Commun Biol. 6(1):952

Nguyen T K T, Camp C R, Doan J K, Traynelis S F, Sloan S A, Hall R A. (2023) GPR37L1 controls maturation and organization of cortical astrocytes during development. Glia. 71(8): 1921-1946

Camp C R, Traynelis S F. (2023) Additional Depth to the NMDA Receptor Hypofunction and Parvalbumin Cell Dysfunction Hypotheses of Schizophrenia. Biol Psychiatry. 94(4): 283-284

Zaczek R, Traynelis S F, Dingledine R, Koszalka G W, Laskowitz D T. (2023) Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor. Clin Pharmacol Drug Dev. 12(7): 706-717

Xie L, McDaniel M J, Perszyk R E, Kim S, Cappuccio G, Shapiro K A, Muñoz-Cabello B, Sanchez-Lara P A, Grand K, Zhang J, Nocilla K A, Sheikh R, Armengol L, Romano R, Pierson T M, Yuan H, Myers S J, Traynelis S F. (2023) Functional effects of disease-associated variants reveal that the S1-M1 linker of the NMDA receptor critically controls channel opening. Cell Mol Life Sci. 80(4): 110

Brünger T, Pérez-Palma E, Montanucci L, Nothnagel M, Møller R S, Schorge S, Zuberi S, Symonds J, Lemke J R, Brunklaus  A, Traynelis S F, May P, Lal D. (2023) Conserved patterns across ion channels correlate with variant pathogenicity and clinical phenotypes. Brain. 146(3): 923-934

Harris L D, Regan M C, Myers S J, Nocilla K A, Akins N S, Tahirovic Y A, Wilson L J, Dingledine R, Furukawa H, Traynelis S F, Liotta D C. (2023) Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model. ACS Chem Neurosci. 14(5): 917-935

Brock S, Laquerriere A, Marguet F, Myers S J, Yuan H, Baralle D, Vanderhasselt T, Stouffs  K, Keymolen K, Kim S, Allen J, Shaulsky G, Chelly  J, Marcorelle P, Aziza J, Villard L, Sacaze E, Y de Wit M C, Wilke M, Mancini G M S, Hehr U, Lim D, Mansour S, Traynelis S F, Beneteau C, Denis-Musquer M, Jansen A C, Fry A E, Bahi-Buisson N. (2023) Overlapping cortical malformations in patients with pathogenic variants in GRIN1 and GRIN2B. J Med Genet. 60(2): 183-192

Tang W, Beckley J T, Zhang J, Song R, Xu Y, Kim S, Quirk M C, Robichaud A J, Diaz E S, Myers S J, Doherty J J, Ackley M A, Traynelis S F, Yuan H. (2023) Novel neuroactive steroids as positive allosteric modulators of NMDA receptors: mechanism, site of action, and rescue pharmacology on GRIN variants associated with neurological conditions. Cell Mol Life Sci. 80(2): 42

Montañez-Miranda C, Perszyk R E, Harbin N H, Okalova J, Ramineni S, Traynelis S F, Hepler J R. (2023) Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling Predicted by Three-Dimensional Missense Tolerance Ratio Analysis. Mol Pharmacol. 103(1): 27-37

Chou T H, Kang H, Simorowski N, Traynelis S F, Furukawa H. (2022) Structural insights into assembly and function of GluN1-2C, GluN1-2A-2C, and GluN1-2D NMDARs. Mol Cell. 82(23): 4548-4563           

Strehlow V, Rieubland C, Gallati S, Kim S, Myers S J, Peterson V, Ramsey A J, Teuscher D D, Traynelis S F, Lemke J R. (2022) Compound-heterozygous GRIN2A null variants associated with severe developmental and epileptic encephalopathy. Epilepsia. 63(10): e132-e137

Han W, Yuan H, Allen J P, Kim S, Shaulsky G H, Perszyk R E, Traynelis S F, Myers S J. (2022) Opportunities for Precision Treatment of GRIN2A and GRIN2B Gain-of-Function Variants in Triheteromeric N-Methyl-D-Aspartate Receptors. J Pharmacol Exp Ther. 381(1): 54-66

Benke T A, Park K, Krey I, Camp C R, Song R, Ramsey A J, Yuan H, Traynelis S F, Lemke J. (2021) Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs. Neuropharmacology. 199: 108805 

Hansen K B, Wollmuth L, Bowie D, Furukawa H, Menniti F S, Sobolevsky A I, Swanson G T, Swanger S A, Greger I H, Nakagawa T, McBain C J, Jayaraman V, Low C M, Dell’Acqua M L, Diamond J S, Camp C R, Perszyk R E, Yuan H, Traynelis S F. (2021) Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels. Pharmacol Rev. 73(4): 298-487 

Myers S J, Ruppa K P, Wilson L J, Tahirovic Y A, Lyuboslavsky P, Menaldino D S, Dentmom Z W, Koszalka G W, Zaczek R, Dingledine R J, Traynelis S F, Liotta D C. (2021) A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use. J Pharmacol Exp Ther. 379(1): 41-52

Zhang J, Tan W, Bhatia N K, Xu Y, Paudyal N, Liu D, Kim S, Song R, XiangWei W, Shaulsky G, Myers S J, Dobyns W, Jayaraman V, Traynelis S F, Yuan H, Bozarth X. (2021) A de novo GRIN1 Variant Associated With Myoclonus and Developmental Delay: From Molecular Mechanism to Rescue Pharmacology. Front Genet. 12: 694312

Perszyk R E, Kristensen A S, Lyuboslavsky P, Traynelis S F. (2021) Three-dimensional missense tolerance ratio analysis. Genome Res. 31(8): 1447-1461

Xu Y, Song R, Chen W, Strong K, Shrey D, Gedela S, Traynelis S F, Zhang G, Yuan H. (2021) Recurrent seizure-related GRIN1 variant: Molecular mechanism and targeted therapy. Ann Clin Transl Neurol. 8(7): 1480-1494 

Park H, Han K S, Seo J, Lee J, David S M, Woo J, Chun H, Cho S, Bae J Y, An H, Jok W, Yoon B E, Berlinguer-Palmini R, Mannaioni G, Traynelis S F, Bae Y C, Choi S Y, Justin Lee C. (2021) Correction to: Channel-mediated astrocytic glutamate modulates hippocampal synaptic plasticity by activating postsynaptic NMDA receptors. Mol Brain. 14(1):103

Perszyk R E, Yip M C, McConnell O L, Wang E T, Jenkins W, Traynelis S F, Forest C R. (2021) Automated Intracellular Pharmacological Electrophysiology for Ligand-Gated Ionotropic Receptor and Pharmacology Screening. Mol Pharmacol. 100(1): 73-82

Perszyk R E, Zheng Z, Banke T G, Zhang J, Xie L, McDaniel M J, Katzman B M, Pelly S C, Yuan H, Liotta D C, Traynelis S F. (2021) The Negative Allosteric Modulator EU1794-4 Reduces Single-Channel Conductance and Ca2+ Permeability of GluN1/GluN2A N-Methyl-d-Aspartate Receptors. Mol Pharmacol. 99(5): 399-411\ 

Strong K L, Epplin M P, Ogden K K, Burger P B, Kaiser T M, Wilding T J, Kusumoto H, Camp C R, Shaulsky G, Bhattacharya S, Perszyk R E, Menaldino D S, McDaniel M J, Zhang J, Le P, Banke T G, Hansen K B, Huettner J E, Liotta D C, Traynelis S F. (2021) Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of N-Methyl-d-aspartate Receptors. ACS Chem Neurosci. 12(1): 79-98

Tang W, Liu D, Traynelis S F, Yuan H. (2020) Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders. Neuropharmacology. 177: 108247 

Zhu Z, Yi F, Epplin M P, Liu D, Summer S L, Mizu R, Shaulsky G, XiangWei W, Tang W, Burger P B, Menaldino D S, Myers S J, Liotta D C, Hansen K B, Yuan H, Traynelis S F. (2020) Negative allosteric modulation of GluN1/GluN3 NMDA receptors. Neuropharmacology. 176: 108117

Perszyk R E, Myers S J, Yuan H, Gibb A J, Furukawa H, Sobolevsky A I, Traynelis S F. (2020) Hodgkin-Huxley-Katz Prize Lecture: Genetic and pharmacological control of glutamate receptor channel through a highly conserved gating motif. J Physiol. 598(15): 3071-3083 

Piard J, Bẻreau M, XiangWei W, Wirth T, Amsallem D, Buisson L, Richard P, Liu N, Xu Y, Myers S J, Traynelis S F, Chelly J, Anheim M, Raynaud M, Maldergem L V, Yuan H. (2020) The GRIA3 c.2477G > A Variant Causes an Exaggerated Startle Reflex, Chorea, and Multifocal Myoclonus. Mov Disord. 35(7): 1224-1232

Amador A, Bostick C D, Olson H, Peters J, Camp C R, Krizay D, Chen W, Han W, Tang W, Kanber A, Kim S, Teoh J, Sah M, Petir S, Paek H, Kim A, Lutz C M, Yang M, Myers S J, Bhattacharya S, Yuan H, Goldstein D B, Poduri A, Boland M J, Traynelis S F, Frankel W N. (2020) Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. Brain. 143(7): 2039-2057

Epplin M P, Mohan A, Harris L D, Zhu Z, Strong K L, Bacsa J, Le P, Menaldino D S, Traynelis S F, Liotta D C. (2020) Discovery of Dihydropyrrolo[1,2- a]pyrazin-3(4 H)-one-Based Second-Generation GluN2C- and GluN2D-Selective Positive Allosteric Modulators (PAMs) of the N-Methyl-d-Aspartate (NMDA) Receptor. J Med Chem. 63(14): 7569-7600

McDaniel M J, Ogden K K, Kell S A, Burger P B, Liotta D C, Traynelis S F. (2020) NMDA receptor channel gating control by the pre-M1 helix. J Gen Physiol. 152(4): e201912362

Perszyk R E, Swanger S A, Shelley C, Khatri A, Fernandez-Cuervo G, Epplin M P, Zhang J, Lee P, Bülow P, Garnier-Amblard E, Gangireddy P K R, Bassell G J, Yuan H, Menaldino D S, Liotta D C, Liebeskind L S, Traynelis S F. (2020) Biased modulators of NMDA receptors control channel opening and ion selectivity. Nat Chem Biol. 16(2): 188-196v

Traynelis S F, Dlugos D, Henshall D, Mefford H C, Rogawski M A, Staley K J, Dacks P A, Whittemore V, Poduri A, National Institutes of Neurological Disorders and Stroke (NINDS)/American Epilepsy Society (AES) Epilepsy Research Benchmark Stewards. (2020) Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Curr. 20(1_suppl): 23S-30S

Myers S J, Yuan H, Kang J Q, Tan F C K, Traynelis S F, Low C M.  (2019) Distinct roles of GRIN2A and GRIN2B variants in neurological conditions.  F1000Rev-1940.

Li J, Zhang J, Tang W, Mizu R K, Kusumoto H, XiangWei W, Xu Y, Chen W, Amin J B, Hu C, Kannan V, Keller S R, Wilcox W R, Lemke J R, Myers S J, Swanger S A, Wollmuth L P, Petrovski S, Traynelis S F, Yuan H.  (2019) De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases.  Hum Mutat. 40(12): 2393-2413

Regan M C, Zhu Z, Yuan H, Myers S J, Menaldino D S, Tahirovic Y A, Liotta D C, Traynelis S F, Furukawa H. (2019) Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors.  Nat Commun. 10(1): 321

Benke T, Traynelis S F. (2019) AMPA-Type Glutamate Receptor Conductance Changes and Plasticity: Still a Lot of Noise.  Neurochem Res. 44(3): 539-548

Fu H, Tang W, Chen Z, Belov V V, Zhang G, Shao T, Zhang X, Yu Q, Rong J, Deng X, Han W, Myers S J, Giffenig P, Wang L, Josephson L, Shao Y, Davenport A T, Daunais J B, Papisov M, Yuan H, Li Z, Traynelis S F, Liang S H. (2019) Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([18F]N2B-0518) for GluN2B Subunit in the Brain.  ACS Chem Neurosci. 10(5): 2263-2275

Hanson E, Armbruster M, Lau L A, Sommer M E, Klaft Z J, Swanger S A, Traynelis S F, Moss S J, Noubary F, Chadchankar J, Dulla C G. (2019) Tonic activation of GluN2C/GluN2D-containing NMDA receptors by ambient glutamate facilitates cortical interneuron maturation.  J Neurosci. 39(19): 3611-3626

Lumsden E W, Troppoli T A, Myers S J, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang F H, Schmidt S, Jenne C E, Yuan P, Morris P J, Thomas C J, Zarate C A Jr, Moaddel R, Traynelis S F, Pereira E F R, Thompson S M, Albuquerque E X, Gould T D.  (2019) Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Proc Natl Acad Sci U S A. 116(11): 5160-5169

Summer S L, Kell S A, Zhu Z, Moore R, Liotta D C, Myers S J, Koszalka G W, Traynelis S F, Menaldino D S. (2019) Di-aryl Sulfonamide Motif Adds π-Stacking Bulk in Negative Allosteric Modulators of the NMDA Receptor. ACS Med Chem Lett. 10(3):  248-254

XiangWei W, Kannan V, Xu Y, Kosobucki G J, Schulien A J, Kusumoto H, Moufawad El Achkar C, Bhattacharya S, Lesca G, Nguyen S, Helbig K L, Cuisset J M, Fenger C D, Marjanovic D, Schuler E, Wu Y, Bao X, Zhang Y, Dirkx N, Schoonjans A S, Syrbe S, Myers S J, Poduri A, Aizenman E, Traynelis S F, Lemke J R, Yuan H, Jiang Y. (2019) Heterogeneous clinical and functional features of GRIN2D-related developmental and epileptic encephalopathy.  Brain. 142(10): 3009-3027 

Yi F, Bhattacharya S, Thompson C M, Traynelis S F, Hansen K B. (2019) Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.  J Physiol. 597(22): 5495-5514

* Fry AE, Fawcett KA, Zelnik N, Yuan H, Thompson BAN, Shemer-Meiri L, Cushion TD, Mugalaasi H, Sims D, Stoodley N, Chung SK, Rees MI, Patel CV, Brueton LA, Layet V, Giuliano F, Kerr MP, Banne E, Meiner V, Lerman-Sagie T, Helbig KL, Kofman LH, Knight KM, Chen W, Kannan V, Hu C, Kusumoto H, Zhang J, Swanger SA, Shaulsky GH, Mirzaa GM, Muir AM, Mefford HC, Dobyns WB, Mackenzie AB, Mullins JGL, Lemke JR, Bahi-Buisson N, Traynelis SF, Iago HF, Pilz DT.De novo mutations in GRIN1 cause extensive bilateral polymicrogyria. Brain. 2018 Jan 22.

* Singh A, Jenkins MA, Burke KJ Jr, Beck G, Jenkins A, Scimemi A, Traynelis SF, Papa SM. Glutamatergic Tuning of Hyperactive Striatal Projection Neurons Controls the Motor Response to Dopamine Replacement in Parkinsonian Primates. Cell Rep. 2018 Jan 23

* Kaiser TM, Kell SA, Kusumoto H, Shaulsky G, Bhattacharya S, Epplin MP, Strong KL, Miller EJ, Cox BD, Menaldino DS, Liotta DC, Traynelis SF, Burger PB.The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor. Mol Pharmacol. 2018 Feb

* Swanger SA, Vance KM, Acker TM, Zimmerman SS, DiRaddo JO, Myers SJ, Bundgaard C, Mosley CA, Summer SL, Menaldino DS, Jensen HS, Liotta DC, Traynelis SF. A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons. ACS Chem Neurosci. 2018 Feb 21

* Fernández-Marmiesse A, Kusumoto H, Rekarte S, Roca I, Zhang J, Myers SJ, Traynelis SF, Couce ML, Gutierrez-Solana L, Yuan H.A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder. Mov Disord. 2018 Apr 11.

* Regan MC, Grant T, McDaniel MJ, Karakas E, Zhang J, Traynelis SF, Grigorieff N, Furukawa H.Structural Mechanism of Functional Modulation by Gene Splicing in NMDA Receptors. Neuron. 2018 May 2.

* Perszyk R, Katzman BM, Kusumoto H, Kell SA, Epplin MP, Tahirovic YA, Moore RL, Menaldino D, Burger P, Liotta DC, Traynelis SF. AN NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups. Elife. 2018 May 24.

* Gibb A, Ogden KK, McDaniel MJ, Vance KM, Kell SA, Butch C, Burger P, Liotta DC, Traynelis SF.A structurally-derived model of subunit-dependent NMDA receptor function. J Physiol. 2018 Jun 19. 

* Bhattacharya S, Ma Y, Dunn AR, Bradner JM, Scimemi A, Miller GW, Traynelis SF, Wichmann T. NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate. J Neurosci Res. 2018 Jul.

Bhattacharya S, Khatri A, Swanger SA, DiRaddo JO, Yi F, Hansen KB, Yuan H, Traynelis SF.   Triheteromeric GluN1/GluN2A/GluN2C NMDARs with Unique Single-Channel Properties Are the Dominant Receptor Population in Cerebellar Granule Cells.  Neuron 2018, Jul 25.

* Swanger SA, Traynelis SF. Synaptic receptor diversity revealed across space and time. Tr Neurosci. 2018 Aug.

*Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, Traynelis SF. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018 Aug.

* Wells G, Yuan H, McDaniel MJ, Kusumoto H, Snyder JP, Liotta DC, Traynelis SF. The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening. Proteins, Structure, Function and Bioinformatics. 2018 Oct 5.

*  Ogden KK, Chen W, Swanger SA, McDaniel MJ, Fan LZ, Hu C, Tankovic A, Kusumoto H, Kosobucki GJ, Schulien AJ, Su Z, Pecha J, Bhattacharya S, Petrovski S, Cohen AE, Aizenman E, Traynelis SF, Yuan H. Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology. PLoS Genet. 2017 Jan 17

* Chen W, Tankovic A, Burger P, Traynelis SF, Yuan H. Functional evaluation of a de novo GRIN2A mutation identified in a patient with profound global developmental delay and refractory epilepsy. Molecular Pharmacology. Jan 2017.

* Gao K, Tankovic S, Zhang Y, Chen W, Wei WX, Hu C, Traynelis SF, Yuan H, Jiang Y. A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia. PLOS One. Feb 2017.

* Chen W, Shieh C, Swanger SA, Tankovic A, Au M, McGuire M, Tagliati M, Graham JM, Madan-Khetarpa S, Traynelis SF, Yuan H, Pierson TM (2017) GRIN1 mutation associated with intellectual disability alters NMDA receptor trafficking and function. J Human Genetics, Feb 2017.

* Liu S, Zhou L, Yuan H, Vieira M, Sanz-Clemente A, Badger JD 2nd, Lu W, Traynelis SF, Roche KW.A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density. J Neurosci. 2017 Apr 12;37(15):4093-4102. doi: 10.1523/JNEUROSCI.0827-16.2017. Epub 2017 Mar 10.

* Platzer K, Yuan H, Schütz H, Winschel A, Chen W, Hu C, Kusumoto H, Heyne HO, Helbig KL, Tang S, Willing MC, Tinkle BT, Adams DJ, Depienne C, Keren B, Mignot C, Frengen E, Strømme P, Biskup S, Döcker D, Strom TM, Mefford HC, Myers CT, Muir AM, LaCroix A, Sadleir L, Scheffer IE, Brilstra E, van Haelst MM, van der Smagt JJ, Bok LA, Møller RS, Jensen UB, Millichap JJ, Berg AT, Goldberg EM, De Bie I, Fox S, Major P, Jones JR, Zackai EH, Abou Jamra R, Rolfs A, Leventer RJ, Lawson JA, Roscioli T, Jansen FE, Ranza E, Korff CM, Lehesjoki AE, Courage C, Linnankivi T, Smith DR, Stanley C, Mintz M, McKnight D, Decker A, Tan WH, Tarnopolsky MA, Brady LI, Wolff M, Dondit L, Pedro HF, Parisotto SE, Jones KL, Patel AD, Franz DN, Vanzo R, Marco E, Ranells JD, Di Donato N, Dobyns WB, Laube B, Traynelis SF, Lemke JR.GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J Med Genet. 2017 Jul;54(7):460-470. doi: 10.1136/jmedgenet-2016-104509. Epub 2017 Apr 4. PMID: 28377535 Free PMC Article

* Strong KL, Epplin MP, Bacsa J, Butch CJ, Burger PB, Traynelis SF , Liotta DC. The structure-activity relationship of a tetrahydroisoquinoline class of N-methyl-ᴅ-aspartate receptor modulators that potentiates GluN2B-containing NMDA receptors.  2017.  J Med Chem. June 2017 

* Yi F, Traynelis SF, Hansen KB.Selective Cell-Surface Expression of Triheteromeric NMDA Receptors. Methods Mol Biol. 2017

* Hansen KB, Yi F, Perszyk RE, Menniti FS, Traynelis SF.NMDA Receptors in the Central Nervous System. Methods Mol Biol. 2017

* Galtieri DJ, Estep CM, Wokosin DL, Traynelis S, Surmeier DJ.Pedunculopontine glutamatergic neurons control spike patterning in substantia nigra dopaminergic neurons. Elife. 2017 Oct 5

* Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016 Apr 29.

* Kristensen AS, Hansen KB, Naur P, Olsen L, Kurtkaya NL, Dravid SM, Kvist T, Yi F, Pøhlsgaard J, Clausen RP, Gajhede M, Kastrup JS, Traynelis SF. Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors. Mol Pharmacol. 2016 Feb.

* Gyoneva S, Weinshenker D, Traynelis SF. Altered motility of plaque-associated microglia in a model of Alzheimer’s disease. Neuroscience. June 2016.

* Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick EM, Kosobucki GJ, Chen W, Schulien AJ, Chiavacci R, Tankovic A, Naase C, Brueckner F, von Stülpnagel-Steinbeis C, Hu C, Kusumoto H, Hedrich UB, Elsen G, Hörtnagel K, Aizenman E, Lemke JR, Hakonarson H, Traynelis SF, Falk MJ. GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. American Journal of Human Genetics.  Sept 2016.

* Hu C, Chen W,Myers SJ, Yuan H, Traynelis SF. Human GRIN2B variants in neurodevelopmental disorders.  Journal of Pharmacological Sciences. October 2016.

* Swanger SA, Chen W, Wells G, Burger PB, Tankovic A, Bhattacharya S, Strong KL, Hu C, Kusumoto H, Zhang J, Adams DR, Millichap JJ, Petrovski S, Traynelis SF, Yuan H.  Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains. American Journal of Human Genetics. Nov 2016.

* Perszyk RE, DiRaddo JO, Strong KL, Low CM, Ogden KK, Khatri A, Vargish GA, Pelkey KA, Tricoire L, Liotta DC, Smith Y, McBain CJ, Traynelis SF. GluN2D-containing N-methyl-D-aspartate receptors mediate synaptic transmission in hippocampal interneurons and regulate interneuron activity. Molecular Pharmacology. Dec 2016.

* Tamborini L, Chen Y, Foss CA, Pinto A, Horti AG,  Traynelis SF, De Micheli C, Mease RC, Hansen KB, Conti P, Pomperb MG. Development of radiolabeled ligands targeting the glutamate binding site of NMDA receptors as potential brain imaging agents. Journal of Medicinal Chemistry.  Dec 2016.

*Swanger SA, Vance KM, Pare JF, Sotty F, Fog K, Smith Y, Traynelis SF. NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus. J Neurosci. 2015 Dec 2.

* Butler AJ, Kallos J, Housley SN, LaPlaca MC, Traynelis SF, Wolf SL. Randomized, Placebo-Controlled, Double-Blind Pilot Study of D-Cycloserine in Chronic Stroke. Rehabil Res Pract. 2015.

* Katzman BM, Perszyk RE, Yuan H, Tahirovic YA, Sotimehin AE, Traynelis SF, Liotta DC. A novel class of negative allosteric modulators of NMDA receptor function. Bioorg Med Chem Lett. 2015 Dec 1.

* EpiPM Consortium: Berkovic SF, Scheffer IE, Petrou S, Delanty N, Dixon-Salazar TJ, Dlugos DJ, Helbig I, Frankel WN, Goldstein DB, Heinzen EL, Lowenstein DH, Mefford HC, Parent JM, Poduri A, Traynelis SF. A roadmap for precision medicine in the epilepsies. Lancet Neurol. 2015 Dec.

* Brown JH, Catterall WA, Conn PJ, Cull-Candy SG, Dingledine R, Harden TK, Insel PA, Milligan G, Traynelis SF. The First 50 Years of Molecular Pharmacology. Mol Pharmacol. 2015 Jul.

* Yuan H, Low CM, Moody OA, Jenkins A, Traynelis SF. Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases. Mol Pharmacol. 2015 Jul.

* Heinzen EL, Neale BM, Traynelis SF, Allen AS, Goldstein DB. The genetics of neuropsychiatric diseases: looking in and beyond the exome. Annu Rev Neurosci. 2015 Jul 8.

* Yuan H, Myers SJ, Wells G, Nicholson KL, Swanger SA, Lyuboslavsky P, Tahirovic YA, Menaldino DS, Ganesh T, Wilson LJ, Liotta DC, Snyder JP, Traynelis SF. Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. Neuron. 2015 Mar 18.

* Park H, Han KS, Seo J, Lee J, Dravid SM, Woo J, Chun H, Cho S, Bae JY, An H, Koh W, Yoon BE, Berlinguer-Palmini R, Mannaioni G, Traynelis SF, Bae YC, Choi SY, Lee CJ. Channel-mediated astrocytic glutamate modulates hippocampal synaptic plasticity by activating postsynaptic NMDA receptors. Mol Brain. 2015 Feb 3.

* Strong KL, Jing Y, Prosser AR, Traynelis SF, Liotta DC. NMDA receptor modulators: an updated patent review (2013-2014). Expert Opin Ther Pat. 2014 Dec.

* Hansen KB, Traynelis SF. Glutamate receptors: mechanistic twists and turns. Nat Chem Biol. 2014 Sep.

* Khatri A, Burger PB, Swanger SA, Hansen KB, Zimmerman S, Karakas E, Liotta DC, Furukawa H, Snyder JP, Traynelis SF. Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator. Mol Pharmacol. 2014 Nov.

* Poulsen MH, Andersen J, Christensen R, Hansen KB, Traynelis SF, Strømgaard K, Kristensen AS. Binding of argtx-636 in the NMDA receptor ion channel. J Mol Biol. 2014 May 23.

* Gyoneva S, Davalos D, Biswas D, Swanger SA, Garnier-Amblard E, Loth F, Akassoglou K, Traynelis SF. Systemic inflammation regulates microglial responses to tissue damage in vivo. Glia. 2014 May 7.

* Gyoneva S, Shapiro L, Lazo C, Garnier-Amblard E, Smith Y, Miller GW, Traynelis SF. Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease. Neurobiol Dis. 2014 Jul.

* Jenkins MA, Wells G, Bachman J, Snyder JP, Jenkins A, Huganir RL, Oswald RE, Traynelis SF. Regulation of GluA1 a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor function by protein kinase C at serine-818 and threonine-840. Mol Pharmacol. 2014 Apr.

* Adams DR, Yuan H, Holyoak T, Arajs KH, Hakimi P, Markello TC, Wolfe LA, Vilboux T, Burton BK, Fajardo KF, Grahame G, Holloman C, Sincan M, Smith AC, Wells GA, Huang Y, Vega H, Snyder JP, Golas GA, Tifft CJ, Boerkoel CF, Hanson RW, Traynelis SF, Kerr DS, Gahl WA. Three rare diseases in one Sib pair: RAI1, PCK1, GRIN2B mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity. Mol Genet Metab. 2014 Apr 13.

* Zimmerman SS, Khatri A, Garnier-Amblard EC, Mullasseril P, Kurtkaya NL, Gyoneva S, Hansen KB, Traynelis SF, Liotta DC. Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators. J Med Chem. 2014 Mar 27.      - Correction

* Hansen KB, Ogden KK, Yuan H, Traynelis SF. Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron. 2014 Mar 5.

* Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, Markello T, Golas G, Simeonov DR, Holloman C, Tankovic A, Karamchandani MM, Schreiber JM, Mullikin JC; PhD for the NISC Comparative Sequencing Program, Tifft CJ, Toro C, Boerkoel CF, Traynelis SF, Gahl WA. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol. 2014 Mar 1.

* Yuan H, Hansen KB, Zhang J, Pierson TM, Markello TC, Fajardo KV, Holloman CM, Golas G, Adams DR, Boerkoel CF, Gahl WA, Traynelis SF. Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy. Nat Commun. 2014.

* Kvist T, Steffensen TB, Greenwood JR, Tabrizi FM, Hansen KB, Gajhede M, Pickering DS, Traynelis SF, Kastrup JS, Bräuner-Osborne H. Crystal Structure and Pharmacological Characterization of a Novel NMDA Receptor Antagonist at the GluN1 Glycine Binding Site. J Biol Chem. 2013 Sep 26.

* Ogden KK, Khatri A, Traynelis SF, Heldt SA. Potentiation of GluN2C/D NMDA Receptor Subtypes in the Amygdala Facilitates the Retention of Fear and Extinction Learning in Mice. Neuropsychopharmacology. 2013 Sep 6.

* Kvist T, Greenwood JR, Hansen KB, Traynelis SF, Bräuner-Osborne H. Structure-based discovery of antagonists for GluN3-containing N-methyl-d-aspartate receptors. Neuropharmacology. 2013 Aug 22.

* Acker TM, Khatri A, Vance KM, Slabber C, Bacsa J, Snyder JP, Traynelis SF, Liotta DC. Structure-Activity Relationships and Pharmacophore Model of a Noncompetitive Pyrazoline Containing Class of GluN2C/GluN2D Selective Antagonists. J Med Chem. 2013 Aug 22.

* Vance KM, Hansen KB, Traynelis SF. Modal gating of GluN1/GluN2D NMDA receptors. Neuropharmacology. 2013 Aug.

* Hansen KB, Tajima N, Risgaard R, Perszyk RE, Jørgensen L, Vance KM, Ogden KK, Clausen RP, Furukawa H, Traynelis SF. Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors. Mol Pharmacol. 2013 Jul.

* Gyoneva S, Traynelis SF. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J Biol Chem. 2013 May 24.

* Risgaard R, Nielsen SD, Hansen KB, Jensen CM, Nielsen B, Traynelis SF, Clausen RP. Development of 2'-substituted (2S,1'R,2'S)-2-(carboxycyclopropyl)glycine analogues as potent N-methyl-d-aspartic acid receptor agonists. J Med Chem. 2013 May 23.

* Santangelo Freel RM, Ogden KK, Strong KL, Khatri A, Chepiga KM, Jensen HS, Traynelis SF, Liotta DC. Synthesis and Structure Activity Relationship of Tetrahydroisoquinoline-Based Potentiators of GluN2C and GluN2D Containing N-Methyl-d-aspartate Receptors. Mol Pharmacol. 2013 Mar 1.      - Correction

* Ogden KK, Traynelis SF. Contribution of the M1 Transmembrane Helix and Pre-M1 Region to Positive Allosteric Modulation and Gating of N-Methyl-D-Aspartate Receptors. Mol Pharmacol. 2013 Mar 1.

* Selvakumar B, Jenkins MA, Hussain NK, Huganir RL, Traynelis SF, Snyder SH. S-nitrosylation of AMPA receptor GluA1 regulates phosphorylation, single-channel conductance, and endocytosis. Proc Natl Acad Sci U S A. 2013 Jan 15.

* Selvakumar B, Jenkins MA, Hussain NK, Huganir RL, Traynelis SF, Snyder SH. S-nitrosylation of AMPA receptor GluA1 regulates phosphorylation, single-channel conductance, and endocytosis. Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1077-82.

* Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC. Novel NMDA receptor modulators: an update. Expert Opin Ther Pat. 2012 Nov;22(11):1337-52.

* Oh SJ, Han KS, Park H, Woo DH, Kim HY, Traynelis SF, Lee CJ. Protease activated receptor 1-induced glutamate release in cultured astrocytes is mediated by Bestrophin-1 channel but not by vesicular exocytosis. Mol Brain. 2012 Oct 12;5:38.

* Hedegaard M, Hansen KB, Andersen KT, Bräuner-Osborne H, Traynelis SF. Molecular pharmacology of human NMDA receptors. Neurochem Int. 2012 Sep;61(4):601-9.

* Vance KM, Hansen KB, Traynelis SF. GluN1 splice variant control of GluN1/GluN2D NMDA receptors. J Physiol. 2012 Aug 15;590(Pt 16):3857-75.

* Burger PB, Yuan H, Karakas E, Geballe M, Furukawa H, Liotta DC, Snyder JP, Traynelis SF. Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators. Mol Pharmacol. 2012 Aug;82(2):344-59.

* McCoy KL, Gyoneva S, Vellano CP, Smrcka AV, Traynelis SF, Hepler JR. Protease-activated receptor 1 (PAR1) coupling to G(q/11) but not to G(i/o) or G(12/13) is mediated by discrete amino acids within the receptor second intracellular loop. Cell Signal. 2012 Jun;24(6):1351-60.

* Hansen KB, Ogden KK, Traynelis SF. Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J Neurosci. 2012 May 2;32(18):6197-208.
     - Recommended on F1000Prime

* Wyllie DJ, Traynelis SF. NMDA receptor permeation: a light in the tunnel. Nat Neurosci. 2012 Feb 24;15(3):343-4.

* Jenkins MA, Traynelis SF. PKC phosphorylates GluA1-Ser831 to enhance AMPA receptor conductance. Channels (Austin). 2012 Jan 1;6(1).

* Traynelis SF. Editor's note: technological advances and a molecular understanding of pharmacology. Mol Pharmacol. 2012 Jan;81(1):1-2.

* Ogden KK, Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci. 2011 Dec;32(12):726-33.

* Acker TM, Yuan H, Hansen KB, Vance KM, Ogden KK, Jensen HS, Burger PB, Mullasseril P, Snyder JP, Liotta DC, Traynelis SF. Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95.

* Li F, Wang W, Gu M, Gyoneva S, Zhang J, Huang S, Traynelis SF, Cai H, Guggino SE, Zhang X. L-type calcium channel activity in osteoblast cells is regulated by the actin cytoskeleton independent of protein trafficking. J Bone Miner Metab. 2011 Sep;29(5):515-25

* Han KS, Mannaioni G, Hamill CE, Lee J, Junge CE, Lee CJ, Traynelis SF. Activation of protease activated receptor 1 increases the excitability of the dentate granule neurons of hippocampus. Mol Brain. 2011 Aug 10;4:32.

* Hansen KB, Traynelis SF. How glutamate receptor subunits mix and match: details uncovered. Neuron. 2011 Jul 28;71(2):198-200.

* Kristensen AS, Jenkins MA, Banke TG, Schousboe A, Makino Y, Johnson RC, Huganir R, Traynelis SF. Mechanism of Ca2+/calmodulin-dependent kinase II regulation of AMPA receptor gating. Nat Neurosci. 2011 Jun;14(6):727-35.

* Hansen KB, Traynelis SF. Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci. 2011 Mar 9;31(10):3650-61.

* Vance KM, Simorowski N, Traynelis SF, Furukawa H. Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nat Commun. 2011;2:294.

* Traynelis, SF, Wollmuth, LP, Hansen KB (2011) Structure-function correlates of glutamate-gated ion channels. “Comprehensive Biophysics”, Elsevier (ed E. Egelman) In press 

* Kang SS, Han K-S, Ku BM, Lee YK, Hong J, Shin HY, Almonte AG, Woo DH, Brat DJ, Hwang EM, Yoo SH, Chung CK, Park S-H, Paek SH, Roh EJ, Lee SJ, Park J-Y, Traynelis SF, Lee CJ (2010) Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-triphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Research 70: 1173-83

* McCoy KL, Traynelis SF, Hepler JR (2010) PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signalling pathways to differentially regulate cell physiology. Mol Pharmacol 77: 1005-15

* Hansen KB, Mullasseril P, Dawitt S, Kurtkaya NL, Yuan H, Vance KM, Orr AG, Kvist T, Ogden KK, Le P, Vellano KM, Lewis I, Kurtkaya S, Du Y, Qui M, Snyder JP, Bräuner-Osborne H, Traynelis SF (2010) Implementation of a cell-based screening assay identified H3 antagonists as subunit selective NMDA recpetor antagonists. J Pharmacol Exper Ther 333: 650-662 

* Dravid SM, Prakash A, Berger P, Geballe MT, Yadav R, Le P, Vellano K, Snyder JP, Traynelis, SF (2010) Residues at the ligand binding domain dimer interface control the relative efficacy of D-cycloserine at the NMDA receptors. J Neurosci 30: 2741-54 

* Mosley CA, Acker TM, Hansen KB, Mullasseril P, Andersen KT, Le P, Vellano KM, Brauner-Osborne H, Liotta DC, Traynelis SF (2010) Quinazolin-4-one derivatives: a novel class of noncompetitive NR2C/D subunit-selective NMDA receptor antagonists. J Med Chem 53: 5476-90 

* Hansen KB, Furukawa H, Traynelis SF (2010) Control of assembly and function of glutamate receptors by the amino-terminal domain. Mol Pharmacol 78(4):535-49

* Mullasseril P, Hansen KB, Vance KM, Ogden KK, Yuan H, Kurtkaya NL, Santangelo R, Orr AG, Le P, Vellano KM, Liotta DC, Traynelis SF (2010) A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nature Commun 1(7):1-8

* Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62(3):405-96.

* Chesler M, Traynelis SF (2010) Acid sense and sensibility in the amygdala. Cell Science Commentary 78(4):535-49

* Traynelis, SF, Choi DW (2010) DAPK1 and GluN2B – a deadly link. Cell Science Commentary 78(4):535-49

* Gyoneva S, Orr AG, Traynelis SF (2009) Differential regulation of microglial motility by ATP/ADP and adenosine. Parkinsonism Related Disord 15 Suppl 3:S195-9.

* Yuan H, Hansen KB, Vance KM, Ogden KK, Traynelis SF (2009) Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci 29(39):12045-58.

* Mosley CA, Myers SJ, Murray EE, Santangelo R, Tahirovic YA, Kurtkaya N, Mullasseril P, Yuan H, Lyuboslavsky P, Le P, Wilson LJ, Yepes M, Dingledine R, Traynelis SH, Liotta DC (2009) Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. Bioorg Med Chem 17(17):6463-80.

* Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF (2009) Adenosine A(2A) receptor mediates microglial process retraction. Nature Neurosci12(7):872-8.

* Yuan H, Vance KM, Junge CE, Geballe MT, Snyder JP, Hepler JR, Yepes M, Low CM, Traynelis SF (2009) The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem. 284: 12862-73 

* Hamill CE, Mannaioni G, Lyuboslavsky P, Sastre AA, Traynelis SF (2009) Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Exp Neurol 217(1):136-46.

* Hansen KB, Naur P, Kurtkaya NL, Kristensen AS, Gajhede M, Kastrup JS, Traynelis SF (2009) Modulation of the dimer interface at ionotropic glutamate-like receptor delta2 by D-serine and extracellular calcium. J Neurosci. 29(4): 907-17

* Park, H, Oh SJ, Han KS, Woo DH, Park H, Mannaioni G, Traynelis SF, Lee CJ (2009) Bestrophin-1 encodes for the Ca2+-activated anion channel in hippocampal astrocytes. J Neurosci. 29: 13063-73 

* Ng F-M, Geballe MT, Snyder JP, Traynelis SF, Low C-M (2009) Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies. Molec Brain 1: 16

* Sivaprakasam M, Hansen KB, David O, Nielsen B, Traynelis SF, Clausen RP, Couty F, Bunch L (2009) Sterocontrolled synthesis and pharmacological evaluation of azetidine 2,3-dicarboxylic acids at NMDA receptors. Chem Med Chem 4: 110-7

* Wollmuth L, Traynelis SF (2009) Excitatory view of a receptor. Nature 462: 729-731

* Dravid SM, Prakash A, Traynelis SF (2008) Activation of recombinant NR1/NR2C NMDA receptors. J Physiol. 586: 4425-4439
    -Comment by AJ Plested How 2C a channel that's (almost) not there. J Physiol 586: 4339

* Mannaioni G, Orr AG, Hamill CE, Yuan H, Pedone KH, McCoy KL, Berlinguer Palmini R, Junge CE, Lee CJ, Yepes M, Hepler JR, Traynelis SF (2008) Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocmapal neurons through activation of protease-activated receptor-1. J Biol Chem. 238: 20600-20611

* Erreger K, Traynelis SF (2008) Zinc inhibition of rat NR1/NR2A N-methyl-D-aspartate receptors. J Physiol. 586: 763-778.

* Chen PE, Geballe MT, Katz E, Erreger K, Livesey MR, O'Toole KK, Le P, Lee CJ, Snyder JP, Traynelis SF, Wyllie DJ (2008) Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol.586: 227-245.

* Tahirovic, YA, Geballe M, Gruszecka-Kowalik E, Liotta D, Myers SJ, Lyuboslavsky P, Le P, French A, Irier H, Choi W-B, Easterling K, Yuan H, Wilson LJ, Kotloski R, McNamara JO, Dingledine R, Liotta DC, Traynelis SF, Snyder JP (2008) N-Hydroxypyrazol glycine derivatives as selective N-methyl-d-aspartic acid receptor ligands. J Med Chem 51: 4179-4187.

* Clausen RP, Christensen C, Hansen KB, Greenwood J, Jørgensen L, Micale N, Madsen JC, Nielsen B, Egebjerg J, Bräuner-Osborne H, Traynelis SF, Kristensen JL (2008) Enantiomeric propanolamines as NR2B-selective NMDA receptor antagonists. J Med Chem 51: 5506-5521.

* Yuan H, Geballe MT, Hansen KB, Traynelis SF (2008) Structure and Function of NMDA receptors. “Glutamate Receptors” Eds M Ehlers and J Hell. Springer-Verlag.

* Mannaioni G, Yuan H, Lee CJ, Traynelis SF (2008) Are astrocytes really “stars”? Physiol News 70: 31-33.

 Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, Balster R, Murray TF, Traynelis SF (2007) Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol. 581: 107-128.
    -Comment by G Kohr J Physiol 581:107

* Lee CJ, Mannaioni G, Yuan H, Woo DH, Gingrich MB, Traynelis SF (2007) Astrocytic control of synaptic NMDA receptors. J Physiol. 581: 1057-1081.
    -Comment by Lee & Haydon Astrocytic glutamate targets NMDA receptors J Physiol 581:887.

* Traynelis SF, Trejo J (2007) Protease-activated receptor signaling: new roles and regulatory mechanisms. Curr Opin Hematol. 14: 230-235.

* Hansen KB, Yuan H, Traynelis SF (2007) Structural aspects of AMPA receptor activation, desensitization and deactivation. Curr Opin Neurobiol. 17: 281-288.

* Almonte AG, Hamill CE, Chhatwal JP, Wingo TS, Barber JA, Lyuboslavsky PN, David Sweatt J, Ressler KJ, White DA, Traynelis SF (2007) Learning and memory deficites in mice lacking protease activated receptor-1.  Neurobiol Learn Mem. 88: 295-304.

* Hamill CE, Caudle WM, Richardson JR, Yuan H, Pennell KD, Greene JG, Miller GW, Traynelis SF (2007) Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Mol Pharmacol.72: 653-664.

* Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, Yuan H, Le P, Lyuboslavsky PN, Micale N, Jørgensen L, Clausen RP, Wyllie DJ, Snyder JP, Traynelis SF (2007) Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol. 72: 907-920.

* Naur P, Hansen KB, Kristensen AS, Dravid SM, Pickering DS, Olsen L, Vestergaard B, Egebjerg J, Gajhede M, Traynelis SF, Kastrup JS (2007) Ionotropic glutamate-like receptor delta2 binds D-serine and glycine. Proc Natl Acad Sci U S A. 104: 14116-14121.

* Kristensen A, Hansen KB, Wollmuth L, Egebjerg, J Traynelis SF (2007) Molecular determinant of glutamate receptor function. “The glutamate receptors” (Swanson, Gereau), Humana pp 247-298.

* Kristensen AS, Geballe MT, Snyder JP, Traynelis SF (2006) Glutamate receptors: variation in structure – function coupling. Tr Pharmacol. Sci. 27: 65-69.

* McBain CJ, Traynelis SF (2006) Malevolent lurkers no more: NMDA receptors come of age. J Physiol. 575: 317-318.

* Paquet M, Asay MJ, Fam SR, Inuzuka H, Castleberry AM, Oller H, Smith Y, Yun CC, Traynelis SF, Hall RA (2006) The PDZ scaffold NHERF-2 interacts with mGluR5 and regulates receptor activity. J Biol Chem. 281:29949-29961.

* Dravid SM, Yuan H, Traynelis SF (2006) AMPA receptors molecular biology, pharmacology. "New Encycolopedia of Neuroscience", Ed Larry R. Squire Elsevier Science Limited.

* Erreger K, Traynelis SF (2005) Allosteric interaction between zinc and glutamate binding domains on NR2A causes desensitization of NMDA receptors. J Physiol

* Hamill CE, Goldshmidt A, Nicole O, McKeon RJ, Brat DJ, Traynelis SF (2005) Glial reactivity after damage: implications for scar formation and neuronal recovery Clin Neurosurg 52:29-44.

* Kristensen AS, Traynelis SF (2005) An intrusive chaperone. Nature 435: 1042-1043.

* Erreger K, Geballe MT, Dravid SM, Snyder JP, Wyllie DJ, Traynelis SF (2005) Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analogue. J Neurosci 25: 7858-7866.

* Wong E, Ng F-M, Yu C-Y, Lim P, Lim L-H, Traynelis SF, Low C-M. (2005) Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor. Protein Sci 14: 2275-2283.

* Banke TG, Dravid, SM, Traynelis SF (2005) Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J Neurosci 25: 42-51.

* Erreger K, Dravid SM, Banke TG, Wyllie DJ, Traynelis SF (2005) Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signaling profiles. J Physiol 563:345-358.

* LePage KT, Ishmael JE, Low CM, Traynelis SF, and Murray TF (2005) Differential binding properties of[3H]dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptors. Neuropharmacology 49: 1-16.

* Chen PE, Geballe MT, Stansfeld PJ, Johnston AR, Yuan H, Jacob AL, Synder JP, Traynelis SF, Wyllie DJ (2005) Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol 67:1470–1484.

* Nicole O, Goldshmidt A, Hamill CE, Sorensen SD, Sastre A, Lyuboslavsky P, Hepler JR, McKeon RJ, Traynelis SF (2005) Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. J Neurosci 25(17):4319–4329.

* Fam SR, Paquet M, Castleberry AM, Oller H, Lee CJ, Traynelis SF, Smith Y, Yun CC, Hall RA (2005) P2Y1 receptor signalling is controlled by interaction with the PDZ scaffold NHERF-2. Proc Natl Acad Sci U S A 102(22): 8042-8047.

* Yuan H, Erreger K, Dravid SM, Traynelis SF (2005) Conserved structural and functional control of NMDA receptor gating by transmembrane domain M3. J Biol Chem 280: 29708-29716.

* Holm MM, Lunna M-L, Traynelis SF, Kastrup JS, Egebjerg J (2005) Structural determinants of agonist-specific kinetics at the ionotropic glutamate receptor 2. Proc Natl Acad Sci U S A 102:12053-12058.

* Holm MM, Naur P, Vestergaard B, Geballe, MT, Gajhede M, Kastrup JS, Traynelis SF, Egebjerg J (2005) A binding site tyrosine shapes desensitization kinetics and agonist potency at GluR2: A mutagenic, kinetic, and crystallographic study J Biol Chem 280: 35469-35476.

* Erreger K, Chen P, Wyllie DJA, Traynelis SF (2004) Glutamate receptor gating. CRC Critical Reviews in Neurobiology 16: 187-224.

* Junge CE, Lee CJ, Hubbard KB, Brat D, Hepler JR, Traynelis SF (2004) Expression of PAR1 in human brain tissue. Experimental Neurology 188: 94-103

* Olson E, Lyuboslavsky P, Traynelis SF, McKeon R (2004) PAR-1 deficiency protects against neuronal damage and neurological deficits following unilateral cerebral hypoxia/ischemia. J Cereb Blood Flow Metab 24: 964-971.

* Junge CE, Sugawara T, Olson EE, Lyuboslavsky P, McKeon RJ, Chan PH, Traynelis SF(2004) A Role for Protease Activated Receptor-1 (PAR1) in the neurodegenerative processes of ischemia.“Pharmacology of Cerebral Ischemia” J Krieglstein, S Klumpp (Eds.) Medpharm Scientific Publishers, p 301-311.

* Sorensen SD, Nicole O, Peavy RD, Montoya LM, Traynelis SF, Hepler JR (2003) Common signaling pathways link activation of murine PAR1, LPA, and S1P receptors to proliferation of astrocytes Mol Pharmacol 64: 1199-1209

* Junge CE, Sugawara T, Mannaioni G, Alagarsamy S, Conn PJ, BratD, ChanP, Traynelis SF (2003) The contribution of protease activated receptor-1 to neuronal damage caused by transient focal ischemia. Proc Natl Acad Sci USA 100: 13019-13024

* Jin R, Banke TG, Mayer ML, Traynelis SF, Gouaux E (2003) Structural basis for partial agonist action at ionotropic glutamate receptors.Nature Neuroscience 6: 803-810.

* - Comment by D Weiss, Chang Y "Crystallizing our understanding of partial agonists" Nature Neuroscience 6:788

* Low CM, Lyuboslavsky L, French A, Le P, Wyatte K, Thiel WH, Marchan EM, Igarashi K, Kashiwagi K, Gernert K, Williams K, Traynelis SF Zheng F (2003) Molecular determinants of proton sensitive NMDA receptor gating. Molecular Pharmacology 63: 1212-1222

* - Comment by J Johnson "Acid tests of NMDA receptor gating basics" Mol Pharmacol 63:1199

* Poisik OV, Mannaioni G, Traynelis SF, Smith Y, Conn PJ (2003) Distinct Functional Roles of the Metabotropic Glutamate Receptors 1 and 5 in the Rat Globus Pallidus. J Neurosci 23: 122-130

* Banke TG, Traynelis SF (2003) Activation of NR1/NR2B NMDA receptors. Nature Neuroscience 6: 144-152

        * Comment by Gibb AJ "NMDA receptor gating-uncovered", Tr Neurosci 27:7

* Bowie D, Garcia EP, Marshall J, Traynelis SF, Lange GD (2003) Allosteric regulation and spatial distribution of kainate receptors bound to ancillary proteins in HEK 293 cells. J Physiology 21(9): 3052-3062

* Chesler M, Traynelis SF (2001) Proton release as a modulator of presynaptic function. Neuron 32: 960-962

* Zheng F, Erreger K, Low C-M, Banke T, Lee CJ, Conn PJ, Traynelis SF (2001) An allosteric interaction between the zinc binding site and the glutamate binding site causes fast desensitization of NR1/NR2A receptors. Nature Neurosci 4: 894-901

* Mannaioni G, Marino MJ, Traynelis SF Conn PJ (2001) mGluR1 and mGluR5 receptors differentially regulate CA1 pyramidal cell function J Neurosci 21: 5925-5934

* Mott DD, Erreger K, Banke TG, Traynelis SF (2001) Open probability of homomeric murine 5-HT3A serotonin receptors depends on subunit occupancy J Physiol 535: 427-443

* Traynelis SF Lipton SA (2001) Is tissue plasminogen activator a threat to neurons? Nature Medicine 7: 17-18

* Banke TG, Greenwood J, Christensen JK, Liljefors T, Traynelis SF, Schousboe A, Pickering DS (2001) Identification of amino acid residues in glutamate receptor 1 responsible for ligand binding and desensitization. J Neurosci 21(9): 3052-3062

* Banke TG, Bowie D, Lee H-K, Huganir RL, Schousboe A, Traynelis SF (2000) Control of GluR1 AMPA Receptor Function by cAMP-Dependent Protein Kinase. J. Neurosci. 20(1), 89-102.

* Gingrich MB, Junge CE, Lyuboslavsky P, Traynelis SF (2000) Potentiation of NMDA Receptor Function by the Serine Protease Thrombin.J. Neurosci. 20(12), 4582-4595.

* Low CM, Zheng F, Lyuboslavsky P, Traynelis SF (2000) Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors. Proc.Natl.Acad.Sci.USA 97 (20), 11062-11067.

* Gingrich MB, Traynelis SF (2000) Serine proteases and brain damage - is there a link? Trends Neurosci. Sep;23(9):399-407.

Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacological Reviews 51: 7-61.

* Traynelis SF, Jaramillo F (1998) Getting the most out of noise in the central nervous system. Tr. Neurosci. 21: 137-145.

* Wahl P, Anker C, Traynelis SF, Egebjerg J, Rasmussen JS, Krogsgaard-Larsen P, Madsen U (1998) Antagonist properties of phosphono isoxazole amino acid (ATPO) at GluR1-4 AMPA receptor. Mol. Pharmacol. 53: 590-596.

* Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers J (1998) Control of voltage independent zinc inhibition of NMDA receptors by the NR1 subunit. J. Neurosci 18: 6163-6175.

* Zheng F, Gingrich MB, Traynelis SF, Conn PJ (1998) Tyrosine kinase modulates Zn2+ sensitivity of NMDA receptors. Nature Neuroscience1: 185-191.

* Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF, and Dingledine R (1998) Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nature Neuroscience 1: 659-667

* Traynelis SF (1998) Software based correction of single compartment series resistance errors. J. Neurosci. Meth. 86: 25-34.

* Traynelis SF (1998) pH modulation of ligand gated ion channels. in "pH and Brain FUnction (eds. K kaila and BR Ransom) Wiley Liss, NY pp 395-446.

* Traynelis SF, Wahl P (1997) Control of rat GluR6 glutamate receptor open probability by protein kinase A and calcineurin. J. Physiology503: 513-531

* Chung DS, Joshi DS, Murphy TJ, Traynelis SF, Conn PJ (1997) 4-methylhomoibotenic acid activates a novel metabotropic glutamate receptor coupled to phosphoinositide hydrolysis. J. Pharmacol. Exper. Therapeutics 283: 742-749.

* - Comment by MacDonald JF "Phosphorylation targets the functional gating of a glutamate channel" J Physiol 503:469

* Traynelis SF, Hartley M, Heinemann SF (1995) Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines.Science 268: 873-876.

* Sullivan JM, Traynelis SF, Chen H-SV, Escobar W, Heinemann SF, Lipton SA (1994) Identification of two cysteine residues on the NMDAR1 subunit that are required for redox modulation. Neuron 13: 929-936.

* Pulchalski RB, Brose N, Louis J-C, Traynelis SF, Egebjerg J, Lin F, Kukekov V, Wenthold R, Rogers SW, Moran T, Morrison JH, Heinemann, S.F. (1994) Selective RNA editing and subunit assembly of native glutamate receptors. Neuron 13: 131-147.

* Traynelis SF, Silver RA, Cull-Candy SG (1993) Estimated conductance of glutamate receptor-channels activated during EPSCs at the cerebellar mossy fiber-granule cell synapse. Neuron 11: 279-289.

* Wyllie DJA, Traynelis SF, Cull-Candy SG (1993) Evidence for more than one type of non-NMDA receptor in outside-out patches from rat cerebellar granule cells. J. Physiol. 463: 193-226.

* Miller B, Sarantis M, Traynelis SF, Attwell D (1992) Arachidonic acid potentiates NMDA channel currents. Nature 355: 722-725.

* Silver RA, Traynelis SF, Cull-Candy SG (1992) Rapid time-course miniature and evoked excitatory currents at cerebellar synapses in situ. Nature 355: 163-166.

* Traynelis SF, Cull-Candy SG (1991) Pharmacological properties and H+ sensitivity of excitatory amino acid receptor channels in rat cerebellar granule neurones. J. Physiol. 433: 727-763.

* McBain CJ, Traynelis SF, Dingledine R (1990) Regional variation of extracellular space in hippocampus. Science 249: 674-677.

* Traynelis SF, Cull-Candy SG (1990) Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 345: 347-350.

* Kawasaki K, Traynelis SF, Dingledine R (1990) Different responses of CA1 and CA3 regions to hypoxia in the rat hippocampal slice. J. Neurophysiol. 63: 385-394.

* Traynelis SF, Dingledine R, McNamara JO, Butler L, Rigsbee L (1989) Effect of kindling on potassium-induced electrographic seizures in vitro. Neurosci. Lett. 105: 326-332.

* Traynelis SF Dingledine R (1989) Modification of potassium-induced interictal bursts and electrographic seizures by divalent cations. Neurosci. Lett. 98: 194-199.

* Traynelis SF Dingledine R (1989) Role of extracellular space in hyperosmotic suppression of potassium-induced electrographic seizures. J. Neurophysiol. 61: 927-938.

* Traynelis SF Dingledine R (1988) Potassium-induced spontaneous electrographic seizures in the rat hippocampal slice. J. Neurophysiol. 59: 259-277.

* Dingledine R, Boland LM, Chamberlin NL, Kawasaki K, Kleckner NW, Traynelis SF, Verdoorn TA (1988) Amino acid receptors and uptake systems in the mammalian central nervous system. CRC Critical Reviews in Neurobiology 4: 1-96.(n/a)

* Harden TK, Petch LA, Traynelis SF, Waldo GL (1985) Agonist-induced alteration in the membrane form of muscarinic cholinergic receptors. J. Biol. Chem. 260: 13060-13066.